The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
TCT 2021 | KarMMa: characterizing incidence of CRS in R/R myeloma
Ankit Kansagra, MD, UT Southwestern Medical Center, Dallas, TX, discusses the results of an analysis examining the incidence of cytokine release syndrome (CRS) in patients enrolled in the KarMMA study (NCT03361748), a Phase II study evaluating the safety and efficacy of idecabtagene vicleucel, a BCMA-targeting CAR-T product in patients with relapsed/refractory (R/R) multiple myeloma. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.
